SCHOTT Pharma AG & Co. KGaA

XTRA:1SXP Stock Report

Market Cap: €4.2b

SCHOTT Pharma KGaA Past Earnings Performance

Past criteria checks 4/6

SCHOTT Pharma KGaA has been growing earnings at an average annual rate of 11.3%, while the Life Sciences industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 6.2% per year. SCHOTT Pharma KGaA's return on equity is 17.7%, and it has net margins of 15.2%.

Key information

11.29%

Earnings growth rate

11.32%

EPS growth rate

Life Sciences Industry Growth26.83%
Revenue growth rate6.16%
Return on equity17.67%
Net Margin15.17%
Next Earnings Update12 Aug 2025

Recent past performance updates

Recent updates

Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued

Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued

We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

Mar 22
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected

Feb 12
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected

Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?

Jan 13
Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
author-image

Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability

SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.

These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't

Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't

SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?

Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?

Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)

Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)

Revenue & Expenses Breakdown

How SCHOTT Pharma KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XTRA:1SXP Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2597314812825
31 Dec 2495513412625
30 Sep 2495715012524
30 Jun 2494915012627
31 Mar 2491613512528
31 Dec 2390615812427
30 Sep 2389915212327
30 Jun 2387314312324
30 Sep 2282112511124
30 Sep 216491019222
30 Sep 20584779024

Quality Earnings: 1SXP has high quality earnings.

Growing Profit Margin: 1SXP's current net profit margins (15.2%) are higher than last year (14.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1SXP's earnings have grown by 11.3% per year over the past 5 years.

Accelerating Growth: 1SXP's earnings growth over the past year (9.6%) is below its 5-year average (11.3% per year).

Earnings vs Industry: 1SXP earnings growth over the past year (9.6%) exceeded the Life Sciences industry -0.7%.

Return on Equity

High ROE: 1SXP's Return on Equity (17.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 10:33
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SCHOTT Pharma AG & Co. KGaA is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav JainBarclays
Victoria LambertBerenberg
Samuel EnglandBerenberg